-
Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the China National Medical Products Administration (NMPA) has accepted a clinical trial application for the combination of two pipeline candidates, ASKC202 tablets and ASK120067 tablets. The company is seeking to evaluate this combination therapy in adults…
-
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the third quarter and the first three quarters of 2023. The company reported a 7% year-on-year (YOY) increase in revenues in constant currency terms for the three-month period, reaching DKK 4.952 billion (USD 709 million). For…
-
Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe
•
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites last week, marking a significant expansion of its manufacturing capabilities. One site is dedicated to biosimilars in Germany, and the other focuses on the production of penicillin active pharmaceutical ingredient (API) in Austria. Investment in…
-
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
•
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023, revealing a 4.1% year-on-year (YOY) decline in organic sales, totaling EUR 5.2 billion (USD 5.5 billion) for the three-month period. The results highlight a challenging environment, with only the Healthcare division showing growth. The Healthcare…
-
Aiming Med Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine
•
Aiming Med, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a strategic partnership with Becton, Dickinson and Co. (BD) during the 6th China International Import Expo (CIIE) in Shanghai this week. This collaboration aims to enhance the application of advanced tumor organoid and single-cell multi-omics…
-
China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel
•
The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT 19), a chimeric antigen receptor (CAR)-T cell therapy developed by Chinese firm Juventas Cell Therapy Ltd. The drug is indicated for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. Inaticabtagene Autoleucel’s…
-
China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)
•
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA) is officially seeking membership. This move signifies the NMPA’s intention to enhance communication and cooperation with PIC/S, aligning with international pharmaceutical inspection standards. Historical Context and PIC/S OverviewPIC/S, formerly the Pharmaceutical Inspection Convention (PIC), was…
-
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
•
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration (FDA) for its once-weekly injection Zepbound (tirzepatide). The drug is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight conditions, including those with at least one…
